Scenario 2: Subcutaneous Biologic Administration for Chronic Disease Management ICD-10: M06.9 (Rheumatoid arthritis, unspecified) A patient with rheumatoid arthritis returns for a scheduled SC injection of a biologic agent (adalimumab)
Strongest human evidence The METAOD006 (OPTIONS) Phase 2b trial randomized 502 adults with obesity (BMI 30-45 kg/m^2) to oral AOD-9604 (0.25, 0.5, or 1 mg/day) or placebo for 24 weeks alongside a supervised diet and exercise program
This approach stacks three fat-loss drivers (fasting, AOD-9604, exercise) into a single window
They can order a blood test to check your levels and recommend the appropriate treatment
No GP referral needed Book directly with us and avoid long GP waiting times
Results showed that the ingredient significantly increased NAD+ levels in senescent fibroblasts, activated the SIRT1 signaling pathway, reduced the expression of senescence-associated -galactosidase (SA--gal), decreased intracellular reactive oxygen species accumulation, and promoted collagen synthesis